Workflow
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Core Viewpoint - Addex Therapeutics is set to report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025, followed by a conference call on October 1, 2025, to discuss the results and provide a business update [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3]. - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3]. - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3]. Upcoming Events - The conference call to discuss the financial results will take place on October 1, 2025, at 16:00 CEST, with participation from CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev [1][2].